Etiology, Pathogenesis, Diagnosis, and Practical Implications of Hepatocellular Neoplasms
暂无分享,去创建一个
[1] X. Wang,et al. Molecular pathogenesis and systemic therapies for hepatocellular carcinoma , 2022, Nature Cancer.
[2] M. Kojima,et al. Component with abundant immune‐related cells in combined hepatocellular cholangiocarcinoma identified by cluster analysis , 2022, Cancer science.
[3] Jakob Nikolas Kather,et al. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. , 2022, Journal of hepatology.
[4] Hepatocellular Neoplasms with Loss of Liver Fatty Acid Binding Protein: Clinicopathologic Features and Molecular Profiling. , 2022, Human pathology.
[5] B. le Bail,et al. Malignant transformation of hepatocellular adenoma , 2022, JHEP reports : innovation in hepatology.
[6] C. Sempoux,et al. Hepatocellular adenoma: what we know, what we do not know, and why it matters , 2021, Histopathology.
[7] A. Luciani,et al. Immune Profiling of Combined Hepatocellular- Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy , 2021, Clinical Cancer Research.
[8] Kathryn J Fowler,et al. Pathologic, Molecular, and Prognostic Radiologic Features of Hepatocellular Carcinoma. , 2021, Radiographics : a review publication of the Radiological Society of North America, Inc.
[9] G. Ioannou. Epidemiology and risk-stratification of NAFLD-associated HCC. , 2021, Journal of hepatology.
[10] V. Miller,et al. Genomic Profiling of Combined Hepatocellular Cholangiocarcinoma Reveals Genomics Similar to Either Hepatocellular Carcinoma or Cholangiocarcinoma , 2021, JCO precision oncology.
[11] Martijn P. D. Haring,et al. Scoping review of clinical practice guidelines on the management of benign liver tumours , 2021, BMJ open gastroenterology.
[12] K. Shanbhogue,et al. Hepatocarcinogenesis: Radiology-Pathology Correlation. , 2021, Magnetic resonance imaging clinics of North America.
[13] C. Balabaud,et al. Hepatocellular Adenoma Risk Factors of Hemorrhage: Size Is Not the Only Concern! , 2021, Annals of surgery.
[14] M. Yeh,et al. Comparing the clinicopathological characteristics of combined hepatocellular–cholangiocarcinoma with those of other primary liver cancers by use of the updated World Health Organization classification , 2021, Histopathology.
[15] Seung‐Mo Hong,et al. Post-resection prognosis of combined hepatocellular carcinoma-cholangiocarcinoma cannot be predicted by the 2019 World Health Organization classification. , 2021, Asian journal of surgery.
[16] J. Morelli,et al. Differentiation of hepatocellular carcinoma from intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in high-risk patients matched to MR field strength: diagnostic performance of LI-RADS version 2018 , 2021, Abdominal Radiology.
[17] C. Sempoux,et al. Predictive Patterns of Glutamine Synthetase Immunohistochemical Staining in CTNNB1-mutated Hepatocellular Adenomas , 2021, The American journal of surgical pathology.
[18] Aurélie Beaufrère,et al. Combined hepatocellular-cholangiocarcinoma: An update. , 2021, Journal of hepatology.
[19] M. Torbenson. Hepatocellular Carcinoma: Making Sense of Morphological Heterogeneity, Growth Patterns, and Subtypes. , 2020, Human pathology.
[20] Johnny C. Hong,et al. Multi-Center Analysis of Liver Transplantation for Combined Hepatocellular Carcinoma-Cholangiocarcinoma Liver Tumors. , 2020, Journal of the American College of Surgeons.
[21] L. Ny,et al. Checkpoint Inhibition Causing Complete Remission of Metastatic Combined Hepatocellular-Cholangiocarcinoma after Hepatic Resection , 2020, Case Reports in Oncology.
[22] Martijn P. D. Haring,et al. A multicentre retrospective analysis on growth of residual hepatocellular adenoma after resection , 2020, Liver international : official journal of the International Association for the Study of the Liver.
[23] C. Sempoux,et al. ASS1 Overexpression: A Hallmark of Sonic Hedgehog Hepatocellular Adenomas; Recommendations for Clinical Practice , 2020, Hepatology communications.
[24] M. Ziol,et al. Clinical Impact of Genomic Diversity From Early to Advanced Hepatocellular Carcinoma , 2020, Hepatology.
[25] M. Ronot,et al. Combining imaging and tumour biopsy improves the diagnosis of combined hepatocellular‐cholangiocarcinoma , 2019, Liver international : official journal of the International Association for the Study of the Liver.
[26] C. Sempoux,et al. Malignant transformation of liver fatty acid binding protein-deficient hepatocellular adenomas: histopathologic spectrum of a rare phenomenon , 2019, Modern Pathology.
[27] J. Zucman‐Rossi,et al. The role of telomeres and telomerase in cirrhosis and liver cancer , 2019, Nature Reviews Gastroenterology & Hepatology.
[28] J. Zucman‐Rossi,et al. Genomic Medicine and Implications for Hepatocellular Carcinoma Prevention and Therapy. , 2019, Gastroenterology.
[29] Kathryn J Fowler,et al. cHCC‐CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation , 2018, Hepatology.
[30] Sang Min Lee,et al. Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging , 2018, European Radiology.
[31] S. Kakar,et al. 13 – Tumours and Tumour-like Lesions of the Liver , 2018 .
[32] M. Nikolski,et al. Argininosuccinate synthase 1 (ASS1): A marker of unclassified hepatocellular adenoma and high bleeding risk , 2017, Hepatology.
[33] H. Tilg,et al. Gut roundtable meeting paper: selected recent advances in hepatocellular carcinoma , 2017, Gut.
[34] Alan D. Lopez,et al. The Burden of Primary Liver Cancer and Underlying Etiologies From 1990 to 2015 at the Global, Regional, and National Level , 2017, JAMA oncology.
[35] S. Imbeaud,et al. Histological subtypes of hepatocellular carcinoma are related to gene mutations and molecular tumour classification. , 2017, Journal of hepatology.
[36] N. Heaton,et al. Histological heterogeneity in primary and metastatic classic combined hepatocellular-cholangiocarcinoma: a case series , 2017, Virchows Archiv.
[37] Steven J. M. Jones,et al. Comprehensive and Integrative Genomic Characterization of Hepatocellular Carcinoma , 2017, Cell.
[38] M. Torbenson. Morphologic Subtypes of Hepatocellular Carcinoma. , 2017, Gastroenterology clinics of North America.
[39] P. Hytiroglou. Well-differentiated hepatocellular nodule: Making a diagnosis on biopsy and resection specimens of patients with advanced stage chronic liver disease. , 2017, Seminars in diagnostic pathology.
[40] S. Imbeaud,et al. Genotype‐phenotype correlation of CTNNB1 mutations reveals different ß‐catenin activity associated with liver tumor progression , 2016, Hepatology.
[41] Y. N. Park,et al. Poor outcome of hepatocellular carcinoma with stemness marker under hypoxia: resistance to transarterial chemoembolization , 2016, Modern Pathology.
[42] A. Luciani,et al. Inflammatory hepatocellular adenomas developed in the setting of chronic liver disease and cirrhosis , 2016, Modern Pathology.
[43] H. Reeves. EASL Clinical Practice Guidelines on the management of benign liver tumours. , 2016, Journal of hepatology.
[44] M. Torbenson,et al. Steatohepatitic variant of hepatocellular carcinoma in the absence of metabolic syndrome or background steatosis: a clinical, pathological, and genetic study. , 2015, Human pathology.
[45] B. Knudsen,et al. Hypoxia after transarterial chemoembolization may trigger a progenitor cell phenotype in hepatocellular carcinoma , 2015, Histopathology.
[46] A. Sepulveda,et al. HepPar-1 and Arginase-1 Immunohistochemistry in Adenocarcinoma of the Small Intestine and Ampullary Region. , 2015, Archives of pathology & laboratory medicine.
[47] Y. Imai,et al. Clinicopathological characteristics of serum amyloid A‐positive hepatocellular neoplasms/nodules arising in alcoholic cirrhosis , 2015, Histopathology.
[48] Jessica Zucman-Rossi,et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets , 2015, Nature Genetics.
[49] J. Zucman‐Rossi,et al. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis , 2014, Hepatology.
[50] Hiromi Nakamura,et al. Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.
[51] V. Vacic,et al. Detection of a Recurrent DNAJB1-PRKACA Chimeric Transcript in Fibrolamellar Hepatocellular Carcinoma , 2014, Science.
[52] J. Calderaro,et al. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions , 2013, Nature Communications.
[53] S. Imbeaud,et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection. , 2013, Gastroenterology.
[54] B. Naini,et al. Chromophobe hepatocellular carcinoma with abrupt anaplasia: a proposal for a new subtype of hepatocellular carcinoma with unique morphological and molecular features , 2013, Modern Pathology.
[55] R. Brody,et al. An inflammatory proposal for hepatocarcinogenesis , 2012, Hepatology.
[56] Angela M. Liu,et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma , 2012, Nature Genetics.
[57] Kevin Struhl,et al. An HNF4α-miRNA Inflammatory Feedback Circuit Regulates Hepatocellular Oncogenesis , 2011, Cell.
[58] Y. N. Park,et al. Human hepatocellular carcinomas with “Stemness”‐related marker expression: keratin 19 expression and a poor prognosis , 2011, Hepatology.
[59] B. Portmann,et al. Mixed phenotype hepatocellular carcinoma after transarterial chemoembolization and liver transplantation , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[60] N. Enomoto,et al. Expression of Keratin 19 Is Related to High Recurrence of Hepatocellular Carcinoma after Radiofrequency Ablation , 2011, Oncology.
[61] G. Grazi,et al. Pre-operative liver biopsy in cirrhotic patients with early hepatocellular carcinoma represents a safe and accurate diagnostic tool for tumour grading assessment. , 2011, Journal of hepatology.
[62] Q. Ye,et al. Risk Factors, Prognosis, and Management of Early and Late Intrahepatic Recurrence After Resection of Primary Clear Cell Carcinoma of the Liver , 2011, Annals of Surgical Oncology.
[63] J. Emond,et al. Steatohepatitic Hepatocellular Carcinoma (SH-HCC): A Distinctive Histological Variant of HCC in Hepatitis C Virus-related Cirrhosis With Associated NAFLD/NASH , 2010, The American journal of surgical pathology.
[64] F. Bosman,et al. WHO Classification of Tumours of the Digestive System , 2010 .
[65] Derek Y. Chiang,et al. Integrative transcriptome analysis reveals common molecular subclasses of human hepatocellular carcinoma. , 2009, Cancer research.
[66] Y. N. Park,et al. The application of markers (HSP70 GPC3 and GS) in liver biopsies is useful for detection of hepatocellular carcinoma. , 2009, Journal of hepatology.
[67] Michiie Sakamoto,et al. Pathologic diagnosis of early hepatocellular carcinoma: A report of the international consensus group for hepatocellular neoplasia , 2009, Hepatology.
[68] Neil D Theise,et al. Hepatic precancerous lesions and small hepatocellular carcinoma. , 2007, Gastroenterology clinics of North America.
[69] Ning Zhang,et al. Outcomes and prognostic factors of cirrhotic patients with hepatocellular carcinoma after radical major hepatectomy , 2007, World Journal of Surgery.
[70] K. Schmitz,et al. Survival and recurrence rates after resection for hepatocellular carcinoma in noncirrhotic livers. , 2007, Journal of the American College of Surgeons.
[71] F. Kondo,et al. Ductular reaction is helpful in defining early stromal invasion, small hepatocellular carcinomas, and dysplastic nodules , 2007, Cancer.
[72] L. Terracciano,et al. Diagnostic value of HSP70, glypican 3, and glutamine synthetase in hepatocellular nodules in cirrhosis , 2007, Hepatology.
[73] S. Boyault,et al. Transcriptome classification of HCC is related to gene alterations and to new therapeutic targets , 2007, Hepatology.
[74] T. Okanoue,et al. Large scaled analysis of hepatitis B virus (HBV) DNA integration in HBV related hepatocellular carcinomas , 2005, Gut.
[75] M. Kojiro,et al. Hepatocellular carcinoma with sarcomatous change: a special reference to the relationship with anticancer therapy , 2004, Cancer Chemotherapy and Pharmacology.
[76] Yoshiki Murakami,et al. Hepatitis B virus-related insertional mutagenesis occurs frequently in human liver cancers and recurrently targets human telomerase gene , 2003, Oncogene.
[77] S. Thorgeirsson,et al. Molecular pathogenesis of human hepatocellular carcinoma , 2002, Nature Genetics.
[78] P Neuhaus,et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis , 2001, Hepatology.
[79] Y. N. Park,et al. “Vascular profiles” of regenerative and dysplastic nodules , 2000, Hepatology.
[80] J. Crowe,et al. Hepatocellular carcinoma arising in the absence of cirrhosis in genetic haemochromatosis: three case reports and review of literature. , 1999, European journal of gastroenterology & hepatology.
[81] A. Wee,et al. Combined Hepatocellular-Cholangiocarcinoma , 1999, Acta Cytologica.
[82] Y. N. Park,et al. Neoangiogenesis and sinusoidal "capillarization" in dysplastic nodules of the liver. , 1998, The American journal of surgical pathology.
[83] S. Thung,et al. Hepatic stellate cell activation in dysplastic nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. , 2008, Liver.
[84] L. Ferrell,et al. Low proliferative activity in macroregenerative nodules: evidence for an alternate hypothesis concerning human hepatocarcinogenesis. , 2008, Liver.
[85] M. Tsuneyoshi,et al. Spindle cell hepatocellular carcinoma: A clinicopathologic and immunohistochemical analysis of 15 cases , 1996, Cancer.
[86] I. Wanless,et al. Terminology of nodular hepatocellular lesions , 1995 .
[87] S. Thung,et al. Macroregenerative nodules in a series of adult cirrhotic liver explants: Issues of classification and nomenclature , 1995, Hepatology.
[88] P. Brissot,et al. Preneoplastic significance of hepatic iron–free foci in genetic hemochromatosis: A study of 185 patients , 1993, Hepatology.
[89] F. Callea,et al. Pathology of hepatocellular carcinoma , 1993, Journal of surgical oncology. Supplement.
[90] D. Woodfield. Hepatocellular carcinoma. , 1986, The New Zealand medical journal.
[91] K. Okita,et al. Morphologic studies of the liver cell dysplasia , 1983, Cancer.
[92] J. V. Campos,et al. [Hepatocellular adenoma]. , 2020, AMB : revista da Associacao Medica Brasileira.